248 related articles for article (PubMed ID: 26413273)
1. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.
Rojas-Rivera J; Fernández-Juárez G; Ortiz A; Hofstra J; Gesualdo L; Tesar V; Wetzels J; Segarra A; Egido J; Praga M
Clin Kidney J; 2015 Oct; 8(5):503-10. PubMed ID: 26413273
[TBL] [Abstract][Full Text] [Related]
2. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
5. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
6. Advances in Membranous Nephropathy.
Ronco P; Plaisier E; Debiec H
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33562791
[TBL] [Abstract][Full Text] [Related]
7. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy.
Rojas-Rivera J; Fervenza FC; Ortiz A
Drugs; 2022 Feb; 82(2):109-132. PubMed ID: 34932208
[TBL] [Abstract][Full Text] [Related]
8. Management of Membranous Nephropathy in Western Countries.
Alfaadhel T; Cattran D
Kidney Dis (Basel); 2015 Sep; 1(2):126-37. PubMed ID: 27536673
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in primary membranous nephropathy: first-line therapy, why not?
Cravedi P; Remuzzi G; Ruggenenti P
Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
[TBL] [Abstract][Full Text] [Related]
10. The STARMEN trial: rethinking calcineurin inhibitor therapy in membranous nephropathy.
Floege J; Rovin BH
Kidney Int; 2021 Apr; 99(4):811-813. PubMed ID: 33745547
[TBL] [Abstract][Full Text] [Related]
11. Primary membranous nephropathy: comprehensive review and historical perspective.
Keri KC; Blumenthal S; Kulkarni V; Beck L; Chongkrairatanakul T
Postgrad Med J; 2019 Jan; 95(1119):23-31. PubMed ID: 30683678
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy.
Ramachandran R; Kumar V; Bharati J; Rovin B; Nada R; Kumar V; Rathi M; Jha V; Gupta KL; Kohli HS
Kidney Int Rep; 2021 Oct; 6(10):2653-2660. PubMed ID: 34622104
[TBL] [Abstract][Full Text] [Related]
13. Management of Membranous Nephropathy in Asia.
Xu J; Hu X; Xie J; Chen N
Kidney Dis (Basel); 2015 Sep; 1(2):119-25. PubMed ID: 27536672
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
15. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
16. Novel Treatments Paradigms: Membranous Nephropathy.
Rojas-Rivera JE; Ortiz A; Fervenza FC
Kidney Int Rep; 2023 Mar; 8(3):419-431. PubMed ID: 36938069
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of primary membranous nephropathy in 2016.
van de Logt AE; Hofstra JM; Wetzels JF
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
[TBL] [Abstract][Full Text] [Related]
18. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P;
J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098
[TBL] [Abstract][Full Text] [Related]
19. Treatment of membranous nephropathy: time for a paradigm shift.
Ruggenenti P; Fervenza FC; Remuzzi G
Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
[TBL] [Abstract][Full Text] [Related]
20. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Rojas-Rivera JE; Carriazo S; Ortiz A
Clin Kidney J; 2019 Oct; 12(5):629-638. PubMed ID: 31583088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]